SEC Form 4 · accession 0001140361-17-019043
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Robert Ajer
Officer — EVP, Chief Commercial Officer
Period of report
May 5, 2017
Accepted (ET)
May 9, 2017 · 1:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 5, 2017 | M | 988 | $28.23 | A | 52,520 | D | |
| Common StockF1,F2 | May 5, 2017 | S | 988 | $99.00 | D | 51,532 | D | |
| Common StockF1 | May 5, 2017 | M | 3,498 | $38.59 | A | 55,030 | D | |
| Common StockF1,F2 | May 5, 2017 | S | 3,498 | $99.00 | D | 51,532 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1,F3 | $28.23 | May 5, 2017 | M | 988 | D | Dec 1, 2011 | May 30, 2021 | Common Stock | 988 | 0 | D |
| Stock Option (Right to buy Common Stock)F1,F3 | $38.59 | May 5, 2017 | M | 3,498 | D | Nov 22, 2008 | May 21, 2018 | Common Stock | 3,498 | 0 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on August 18, 2016.
- F2All shares were sold at the same price.
- F3Reflects the number of stock options outstanding after the transaction from this specific stock option grant.